Survodutide: when can you actually buy it?
You cannot, and this page exists to say so with a date rather than a shrug. Survodutide is a glucagon and GLP-1 receptor dual agonist, given by weekly injection, developed by Boehringer Ingelheim, and it holds no approved application in the United States. Every other page on this site carries a price; this one carries the only public schedule there is instead — the phase 3 trial programme.
When will Survodutide be available, and what will it cost?
No date has been published by anyone, and no price exists because nothing is for sale. What is public is the trial programme, and it sets a floor. Survodutide has 6 phase 3 trials in obesity or overweight registered on ClinicalTrials.gov, enrolling 7,811 people between them, the largest of them 5,531. All 6 have completed, so no trial is outstanding. A sponsor can file on part of a programme rather than wait for the whole of it, so these dates bound the earliest plausible approval rather than predicting one. Drugs@FDA was checked on 2026-08-28 and holds no application for this molecule, against six for semaglutide — the absence is a finding, not a lookup failure.
The trial programme
| Sponsor | Boehringer Ingelheim |
|---|---|
| Approved in the US | no — no application in Drugs@FDA |
| Phase 3 trials in obesity or overweight | 6 |
| Completed | 6 of 6 |
| Still running | 0 |
| Participants enrolled across them | 7,811 |
| Largest single trial | 5,531 participants |
| Last primary completion | programme complete — none outstanding |
Counted from ClinicalTrials.gov on 2026-08-28, restricted to phase 3 studies whose registered condition is obesity, overweight or weight. Approval status checked against Drugs@FDA the same day.
What is worth knowing now
Of the three drugs on these pages, survodutide is the one whose obesity programme is actually finished: all six phase 3 trials in overweight or obesity have completed, the last of them reaching primary completion on 1 June 2026. That last one is also the largest, a cardiovascular safety trial of 5,531 participants, which is the kind of study a regulator wants to see before approving a drug for long-term use in a healthy-ish population. A complete programme is not an approval and not a filing, and Boehringer Ingelheim has published no approval date. What it means is narrower and still useful: there is no longer a trial anyone is waiting on.
Survodutide, answered
- Is Survodutide FDA approved?
- No. Drugs@FDA holds no approved application for it, checked on 2026-08-28. That check is worth stating precisely because the same query returns six applications for semaglutide, so the absence is a real answer rather than a failed search. Until an application is approved there is no legal route to buy it in the United States outside a clinical trial, at any price.
- When will Survodutide be available?
- Nobody has published a date. What can be said is that the waiting is no longer on trials: all 6 phase 3 obesity trials have completed. That removes the usual reason for delay without replacing it with an approval, and Boehringer Ingelheim has announced no date.
- What does Survodutide cost?
- Nothing, because it cannot be bought. There is no list price, no cash price and no savings programme, and any figure circulating is either a forecast or an invention. When it is approved and sold, it will get a card on this site with the price read from the seller's own page and the date it was read, the same as everything else here.
- Can I get survodutide from a compounding pharmacy?
- No, and the reason is structural rather than a matter of availability. Compounding under section 503A starts from an approved drug or a bulk substance the FDA permits; a molecule with no approved application anywhere is not on that footing. Anything sold under this name outside a clinical trial is not a compounded version of an approved drug — it is an unapproved substance, and no pharmacy licence covers that.
What you can buy today
Everything approved for this job, each with the maintenance price read from the seller's own page and the date it was read.
Last updated 2026-08-28 — trial registry and Drugs@FDA checked